Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria.


Journal

The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 11 7 2020
medline: 8 4 2022
entrez: 11 7 2020
Statut: ppublish

Résumé

Dermatologists around the world are still doing their best to report more cutaneous manifestations of the emerging COVID-19 infection. New-onset acute or relapsing chronic urticaria may result from the body's overreacting inflammatory response to infection. The cytokine storm hits different organs in the body, including the skin, leading to activation and degranulation of mast cells with resultant urticaria. Low-dose systemic steroids combined with antihistamines can combat the COVID-19 inflammatory insult and play a role in the control of COVID-19 related severe urticarial attack.

Identifiants

pubmed: 32649228
doi: 10.1080/09546634.2020.1795062
doi:

Substances chimiques

Histamine Antagonists 0
Steroids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1140-1141

Commentaires et corrections

Type : CommentIn

Auteurs

Mohammed Shanshal (M)

Department of Dermatology and Venereology, Specialist Dermatologist at Baghdad Teaching Hospital, Baghdad, Iraq.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH